ICCC PRESS-RELEASE SEC Filing Analysis

Final — all horizons settled through T+60d ⚠ clustered

ICCC ▲ +52.28% at T+60d

NEUTRAL call ✓ call won +52.28% · α vs SPY +40.98% · entry $6.35 → $9.67

Currently $9.68 · +52.44% from $6.35 entry

Entry anchored
Mar 4, 03:52 PM ET
via Databento tick

T+1d

+3.94%

call +3.94% · α +5.25%

$6.60

settled 3mo ago

T+5d

+4.41%

call +4.41% · α +6.65%

$6.63

settled 3mo ago

T+20d

+1.42%

call +1.42% · α +5.21%

$6.44

settled 2mo ago

T+60d

+52.28%

call +52.28% · α +40.98%

$9.67

settled 15d ago

Price Chart

Loading chart...

Executive Summary

ImmuCell reported a 4.3% increase in 2025 product sales to $27.6 million and a significant improvement in gross margin to 41.4% from 30% in 2024, driven by higher volumes and manufacturing efficiencies. Despite a net loss of $1.0 million, down from $2.2 million in 2024, the results were impacted by $3.6 million in non-recurring charges, including asset and inventory write-downs, while operating income turned positive at $1.6 million.

Key Financial Metrics

Revenue

$27.6M

+4.3% YoY

EPS

$-0.12

Actionable Insight

The core business showed meaningful operational improvement with higher sales, better margins, and positive operating income, but the net loss persists due to one-time write-downs. Traders should monitor the Q1 2026 results to see if margin expansion and volume gains are sustainable, and whether the shift in strategy toward First Defense® is driving organic growth.

Key Facts

2025 product sales increased 4.3% to $27.6 million from $26.493 million in 2024
Gross profit margin improved to 41.4% in 2025 from 30% in 2024
Net loss narrowed to $1.0 million in 2025 from $2.2 million in 2024
Non-recurring charges in 2025 totaled $3.6 million, including a $2.7 million Re-Tain® asset write-down and $651,000 in colostrum inventory write-downs
Net operating income turned positive at $1.6 million in 2025 vs. $1.64 million operating loss in 2024
Cash and cash equivalents remained flat at $3.8 million; net working capital increased to $13.0 million

Financial Impact

Revenue increased by $1.15 million; gross profit increased by $3.5 million despite a $1.0 million net loss due to large non-recurring charges

revenuegross_marginnet_lossoperating_incomecash_flow

Risk Factors

Material non-recurring charges ($3.6 million) mask underlying performance and raise concerns about asset valuation and inventory management
Stockholders' equity declined slightly to $27.1 million despite improved operations
Ongoing reliance on one-time items could signal underlying volatility in earnings quality

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3249727

5 reports for ICCC

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for ICCC — sortable, filterable
	Type				Now
May 8, 2026 5w ago	8-K BULLISH ★ 4/10	$8.45 $9.91	▲ +17.28%	▲ +17.36%	$9.68 (+14.56%)
Apr 8, 2026 9w ago	8-K BULLISH ★ 7/10	$7.19 $7.54	▲ +4.87%	▲ +1.68%	$9.68 (+34.63%)
Apr 8, 2026 9w ago	Press Release MIXED ★ 6/10	$7.19 $7.54	▲ +4.87%	▲ +1.68%	$9.68 (+34.63%)
Mar 4, 2026 14w ago	8-K MIXED ★ 6/10	$6.35 $6.63	▲ +4.41%	▲ +6.65%	$9.68 (+52.44%)
Mar 4, 2026 14w ago	Press Release MIXED ★ 6/10	$6.35 $6.63	▲ +4.41%	▲ +6.65%	$9.68 (+52.44%)

US Market Status

Market Closed — Opens Mon (48h 56m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access